Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/1 cls
Achillion (ACHN) Susquehanna Jason Kolbert New Net positive 9% $15.25
Kolbert said ACHN's technology was validated by a 2004 HCV partnership with Gilead (GILD) (see BioCentury, Dec. 6, 2004). He expects catalysts in 1H07 to include Phase II data for lead compound elvucitabine, a nucleoside reverse transcriptase inhibitor for HIV.
Advanced Magnetics (AMAG) Jefferies Adam Walsh Price target Buy 3% $59.10
ThinkEquity Vinny Jindal Price target Buy
Walsh raised his target to $82 from $73 after AMAG's IV ferumoxytol met the primary endpoint of a significant mean change in hemoglobin from baseline in a Phase III trial to treat anemia in patients with chronic kidney disease (CKD) (see BioCentury,

Read the full 1225 word article

How to gain access

Continue reading with a
two-week free trial.